Digital Biopsies: Radiomics and Pathomics Are Important Stops on the Path to Precision Medicine

Digital Biopsies: Radiomics and Pathomics Are Important Stops on the Path to Precision Medicine

Publication date: Oct 05, 2019

With this understanding and the rise of immunotherapy and genomic sequencing, a vast chunk of current cancer research now focuses on finding biomarkers that can predict disease response to certain drugs and guide therapy protocols.

Dr Banna and his colleagues recently published a paper exploring the -promise of digital biopsy” for predicting immunotherapy outcomes based on radiomics and pathomics. 1 Although molecular determinants such as PD-1 or PD-L1 expression, and tumor mutational burden (TMB), are already used in clinical practice, these -fail in consistency, applicability, or reliability to precisely identify the responding patients mainly because of their spatial intratumoral heterogeneity,” they wrote.

Concepts Keywords
Biomarkers Branches of biology
Biopsies Medicine
Biopsy Clinical medicine
Cancer Biomarkers
Digital Biotechnology
Genomic Sequencing Immune system
Heterogeneity Cell biology
Histology Precision medicine
Immunotherapy Radiomics
Lincoln United Immunotherapy
Lincolnshire Wide cancers
Malignancies Specific alteration tumor
Organ
Phenotypes
Precision Medicine
TMB
Tumor

Semantics

Type Source Name
disease MESH cancer
disease DOID cancer
drug DRUGBANK Tropicamide
gene UNIPROT RPL17
gene UNIPROT CD274
gene UNIPROT TBATA

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *